Schrodinger/$SDGR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Schrodinger
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Ticker
$SDGR
Sector
Primary listing
Employees
891
Headquarters
Website
Schrodinger Metrics
BasicAdvanced
$1.3B
-
-$2.40
1.56
-
Price and volume
Market cap
$1.3B
Beta
1.56
52-week high
$28.47
52-week low
$16.60
Average daily volume
1.3M
Financial strength
Current ratio
3.251
Quick ratio
3.092
Long term debt to equity
29.467
Total debt to equity
34.711
Profitability
EBITDA (TTM)
-164.102
Gross margin (TTM)
58.16%
Net profit margin (TTM)
-68.49%
Operating margin (TTM)
-66.34%
Effective tax rate (TTM)
-0.82%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-16.11%
Return on equity (TTM)
-45.67%
Valuation
Price to revenue (TTM)
5.068
Price to book
4.07
Price to tangible book (TTM)
4.14
Price to free cash flow (TTM)
-383.578
Free cash flow yield (TTM)
-0.26%
Free cash flow per share (TTM)
-0.046
Growth
Revenue change (TTM)
32.90%
Earnings per share change (TTM)
-1.97%
3-year revenue growth (CAGR)
14.70%
3-year earnings per share growth (CAGR)
3.81%
What the Analysts think about Schrodinger
Analyst ratings (Buy, Hold, Sell) for Schrodinger stock.
Bulls say / Bears say
Total revenue grew 16% year-over-year to $54.8 million in Q2 2025, driven by 15% software revenue growth and 19% drug discovery revenue growth in both segments (BusinessWire)
The company maintained its full-year 2025 guidance and lowered its operating expense outlook, setting up for better operating leverage as revenue grows (BusinessWire)
An FDA initiative to cut animal testing and broader use of AI-driven drug discovery are driving demand for Schrödinger’s hybrid physics-AI platform, strengthening its leadership in computational molecular discovery (Reuters)
Software gross margin fell to 68% in Q2 2025 from 80% a year ago due to spending on the predictive toxicology initiative, which may put long-term profitability under pressure (BusinessWire)
Schrödinger posted a GAAP net loss of $43.2 million in Q2 2025, highlighting ongoing high operating losses and cash burn even as revenue increases (BusinessWire)
Most proprietary drug candidates are still in Phase I, with initial data for SGR-2921 and SGR-3515 not expected until Q4 2025, which delays any significant drug discovery revenue and increases developmental risk (BusinessWire)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
Schrodinger Financial Performance
Revenues and expenses
Schrodinger Earnings Performance
Company profitability
Schrodinger News
AllArticlesVideos
Schrödinger to Present at Jefferies London Healthcare Conference
Business Wire3 days ago
Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger
Business Wire1 week ago
Schrödinger to Announce Third Quarter 2025 Financial Results on November 5
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Schrodinger stock?
Schrodinger (SDGR) has a market cap of $1.3B as of November 09, 2025.
What is the P/E ratio for Schrodinger stock?
The price to earnings (P/E) ratio for Schrodinger (SDGR) stock is 0 as of November 09, 2025.
Does Schrodinger stock pay dividends?
No, Schrodinger (SDGR) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Schrodinger dividend payment date?
Schrodinger (SDGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Schrodinger?
Schrodinger (SDGR) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.